With the market being conservatively valued at $1-2Bn per year in potential revenues, companies in this space have recently raised sums in excess of $50M to fund their development of products. HaemO2 aims to raise £10M in a series ‘A’ round funding in late 2015/early 2016, and is interested to have discussions with potential investors.
Investor contact: Investors@HaemO2.com
Information on artificial blood: www.drbrandonjreeder.com/artificial-blood
HaemO2 ℅. Dr. Beate Reinhardt, Research and Building Partnerships Manager, University of Essex, Wivenhoe Park, Colchester CO4 3SQ, UK
Dr. Beate Reinhardt: 01206 874110
Prof. Chris Cooper: 01206 872752